RxDoctor Payments Data

Jaime Hernandez-Montfort, MD

Cardiovascular Disease · Round Rock, TXNPI 1235389149

Payments from drug & device makers

$223,292in general payments, 2019–2025

Across 252 payments — averaging $886.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$96K
  • Nuwellis, Inc.$57K
  • Abbott$56K
  • Boston Scientific$6K
  • Novartis$6K
  • Biotronik Inc.$640
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$16,00013%
  • Speaking & faculty fees$71,45058%
  • Travel & lodging$26,43021%
  • Food & beverage$9,2368%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$223,292 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$52,289
Medicare patients
164
Services billed
525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan266$255,611
JardianceEmpagliflozin148$156,096
EliquisApixaban49$38,203
FarxigaDapagliflozin Propanediol29$25,871
Envarsus XrTacrolimus15$19,206
OzempicSemaglutide15$14,340
XareltoRivaroxaban11$7,011
Tacrolimus13$6,442
Torsemide203$4,189
Metoprolol Succinate154$2,921
Amiodarone Hcl38$2,187
Valsartan50$1,876
Spironolactone247$1,824
Eplerenone18$1,360
Atorvastatin Calcium74$1,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$5,695$255,611266 claims
AstraZenecaFarxiga$43$25,87129 claims
Johnson & JohnsonXarelto$37$7,01111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →